{"id":391050,"date":"2016-10-03T00:00:00","date_gmt":"2016-10-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2016-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2016\/"},"modified":"2026-04-22T05:26:35","modified_gmt":"2026-04-22T05:26:35","slug":"dlsfim0006-2016-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2016-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2016\/","title":{"rendered":"Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2016"},"content":{"rendered":"<p>PsA, a disease hallmarked by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF-\u03b1 inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity.\u00a0In recent years, several novel therapies with alternative MOAs, such as the IL-12\/23 inhibitor ustekinumab, the oral PDE-4 inhibitor apremilast, and the\u00a0IL-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who develop inadequate response to TNF-\u03b1 inhibitors.<\/p>\n<p>Currently, three biologics\u00a0and one oral agent are in\u00a0Phase III development for PsA and are expected to launch during the 2015-2025 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies.\u00a0In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF-\u03b1 inhibitor class.<\/p>\n","protected":false},"template":"","class_list":["post-391050","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391050\/revisions"}],"predecessor-version":[{"id":394173,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391050\/revisions\/394173"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}